Vidasym 

Founded by Abbott alumni with extensive new drug R&D experience

Team has advanced multiple therapeutics into clinical development

Alan Lau, Pharm. D. – Interim CEO

Dr. Lau is one of the co-founders of Vidasym. He has conducted over 50 Phase I-IV studies in CKD covering therapeutics such as vitamin D receptor modulators, phosphate binders and others. He serves on the Board of Directors and also as the Renal Scientific Section Chairman of the American Society for Clinical Pharmacology and Therapeutics.  He also serves as Vice-chairman of Nephrology/Urology Expert Committee, United States Pharmacopeia (USP).  Dr. Lau obtained his Doctor of Pharmacy degree at State University of New York at Buffalo, and completed a clinical pharmacy residency at University of Illinois, Chicago.

J. Ruth Wu-Wong, MBA, PhD – President/CSO

Ruth was with Abbott (now AbbVie) for 20+ years where she played a key role in the development of endothelin receptor antagonists including atrasentan which is in clinical studies for diabetic nephropathy.  She was the lead scientist on several novel-target projects at Abbott including the vitamin D receptor agonist project until the project’s termination in 2007.  Dr. Wu-Wong obtained her Ph.D. in biochemistry from Ohio State University and her M.B.A. in finance and management from University of Illinois.

Jin Tian, MD – Clinical Study Consultant

15+ years’ experience in conducting clinical studies, especially in the renal field. Jin has had extensive experience and training in clinical practice and drug development.  Before joining Vidasym, he was the Senior Medical Director at Hoffmann-La Roche Inc. and had successfully completed multiple clinical studies. Before Roche, he was the medical director in charge of clinical studies at Abbott.

Nancy Chou, MS – Clinical Study Project Manager

14+ years’ experience as a clinical study project manager. Nancy has had extensive experience and training in drug discovery and development.  Her previous experience at Abbott includes 14+ years in managing clinical operations covering global clinical trials of all phases, and CRO/vendor management. She was the leader in multiple clinical projects for GCP.

CMC – Ocam Solutions, LLC

Others: Dr. Terry Opgenorth, ex-CEO until 12/2015; Mr. Kinfun Wong, general manager; regulatory affairs specialist; lab personnel (2 chemists, 2 biologists, 2 pharmacologists)